Grape King Bio Ltd (TPE:1707)

Market Cap	17.70B -19.8%
Revenue (ttm)	10.25B -8.1%
Net Income	1.22B -15.9%
EPS	8.17 -15.9%
Shares Out	148.14M
PE Ratio	14.63
Forward PE	12.50
Dividend	6.40 (5.33%)
Ex-Dividend Date	Jun 17, 2026

Volume	83,288
Average Volume	139,177
Open	119.00
Previous Close	120.00
Day's Range	119.00 - 120.00
52-Week Range	117.50 - 147.50
Beta	0.39
RSI	41.16
Earnings Date	Feb 23, 2026

About Grape King Bio

Grape King Bio Ltd, together with its subsidiaries, produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food in Taiwan, China, and internationally. It operates through Multi-Level Marketing; Distributors; Original Design Manufacturer/Original Equipment Manufacturer; and Sales Channel segments. The company offers Chinese herbal medicines, probiotics, energy drinks, and health food supplements for gastrointestinal health, immunity regulation, female beauty, and health care. It also provides functio...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1969
• Employees: 501
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1707

Financial Performance

In 2025, Grape King Bio's revenue was 10.25 billion, a decrease of -8.14% compared to the previous year's 11.16 billion. Earnings were 1.22 billion, a decrease of -15.88%.